• A Sabaté-Llobera, P C Notta, A Benítez-Segura, A López-Ojeda, S Pernas-Simon, M P Boya-Román, and M T Bajén.
• Servicio de Medicina Nuclear, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, España. Electronic address: asabatell@bellvitgehospital.cat.
• Rev Esp Med Nucl Imagen Mol. 2015 Jan 1; 34 (1): 9-12.

AimTo assess the influence of time on the reliability of sentinel lymph node biopsy (SLNB) in breast cancer patients with previous excisional biopsy (EB), analyzing both the sentinel lymph node detection and the lymph node recurrence rate.Material And MethodsThirty-six patients with cT1/T2 N0 breast cancer and previous EB of the lesion underwent a lymphoscintigraphy after subdermal periareolar administration of radiocolloid, the day before SLNB. Patients were classified into two groups, one including 12 patients with up to 29 days elapsed between EB and SLNB (group A), and another with the remaining 24 in which time between both procedures was of 30 days or more (group B). Scintigraphic and surgical detection of the sentinel lymph node, histological status of the sentinel lymph node and of the axillary lymph node dissection, if performed, and lymphatic recurrences during follow-up, were analyzed.ResultsSentinel lymph node visualization at the lymphoscintigraphy and surgical detection were 100% in both groups. Histologically, three patients showed macrometastasis in the sentinel lymph node, one from group A and two from group B. None of the patients, not even those with malignancy of the sentinel lymph node, relapsed after a medium follow-up of 49.5 months (24-75).ConclusionTime elapsed between EB and SLNB does not influence the reliability of this latter technique as long as a superficial injection of the radiopharmaceutical is performed, proving a very high detection rate of the sentinel lymph node without evidence of lymphatic relapse during follow-up.Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

34 keywords...

hide…